JDD March 2024 Issue Highlights
March into groundbreaking dermatological insights with the latest issue of the Journal of Drugs in Dermatology! Explore the prescribing habits of oral minoxidil for androgenetic alopecia, delve into a comprehensive review of botulinum toxin uses, and discover the effectiveness of microneedling for acne scars. Plus, unravel the uncertainties surrounding exosome therapy in androgenetic alopecia. Fro …
March into groundbreaking dermatological insights with the latest issue of the Journal of Drugs in Dermatology! Explore the prescribing habits of oral minoxidil for androgenetic alopecia, delve into a comprehensive review of botulinum toxin uses, and discover the effectiveness of microneedling for acne scars. Plus, unravel the uncertainties surrounding exosome therapy in androgenetic alopecia. Fro … 
Collagen vascular diseases encompass a group of autoimmune disorders that can have a profound impact on an individual's health and quality of life. At the 2023 Skin of Color Update, Dr. Ted Rosen, Professor and Vice-Chair of Dermatology at Baylor College of Medicine, explained how these conditions uniquely impact individuals with skin of color.
Missed the lecture?? Explore key insights and pear … 
Welcome to the December 2023 issue of the Journal of Drugs in Dermatology (JDD), where cutting-edge research and advancements in the field of dermatology take center stage. This issue brings together a diverse array of original articles, case reports, brief communications, and letters to the editor and delves into the latest developments, therapeutic breakthroughs, and cl … 
Baricitinib (Olumiant®) is a once daily oral medication recently FDA approved for severe alopecia areata, which is defined as having a Severity of Alopecia Tool (SALT) score of 50 or higher.1 JAK inhibitors are a relatively new class of drug demonstrating efficacy and safety in a range of inflammatory skin disorders. Emerging studies have highlighted baricitinib’s effectiveness for conditions l … 